The findings of the study will be presented Wednesday, November 10th at the Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia.
The American College of Rheumatology recommends immunofluorescence antinuclear antibody (IF-ANA) testing to help detect the presence of scleroderma specific antinuclear antibodies. Finding the antibodies is a helpful predictor of disease manifestations, clinical course and outcome in scleroderma. However, many commercial labs have recently adopted a newer, automated method that use non-immunofluorescence antinuclear antibody testing. This test is known as NEW ANA.
To test the accuracy of the commercial method for detecting scleroderma antibodies, GUMC researchers evaluated the all test results performed through commercial laboratories of more than 200 scleroderma patients treated in the Georgetown scleroderma clinic between June 2008 and June 2009.
Test results using NEW ANA were available in 58 scleroderma patients. Twenty-eight patients (48 percent) tested negative. Of these 28 patients, 22 had either positive results using IF-ANA or one of the scleroderma specific antibodies. "The NEW ANA testing, that is the ANA test without immunofluorescence, failed to identify patients with a particular subset of scleroderma specific antinuclear antibodies and other patterns that are picked up with IF ANA testing. This finding was significant," says Victoria K Shanmugam, MBBS, MRCP, assistant professor in the Division of Rheumatology, Immunology and Allergy who presented the findings.
NEW ANA test results were not available for the remaining 183 scleroderma patients. IF ANA testing was conducted in these patients and the positive antibody results were divided by subtypes.
"Given what we know about the subsets that are not detected by the NEW ANA testing, it appears that as many as 40 percent of the scleroderma patients would have tested negative using the new commercial testing method," Shanmugam says. "If a clinician has clinical suspicion for scleroderma, they should order the immunofluorescent ANA."
Shanmugam's research is funded by the American College of Rheumatology, Research and Education Foundation, Physician Scientist Development Award and from the National Center for Research Resources.
The authors report no potential financial interests.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Georgetown Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO). In fiscal year 2009-2010, GUMC accounted for 79 percent of Georgetown University's extramural research funding.
Podium presentation: Wednesday, November 10, 2010, 5:45 pm
Abstract:  - Antinuclear Antibody Screening in Systemic Sclerosis.
Donna Rose Swistowski, MD1,Nicole Saddic, MD2,Victoria K Shanmugam, MBBS, MRCP3,Virginia D Steen, MD4. 1Georgetown University Division of Rheumatology, Immunology, and Allergy, Bethesda, MD,2Georgetown University Hospital Department of Medicine,3Georgetown University Division of Rheumatology, Immunology, and Allergy,4Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Purpose: Scleroderma specific antinuclear antibodies (SScAB) are helpful predictors of disease manifestations, clinical course and outcome in scleroderma. Historically, immunofluorescence (IF) antinuclear antibody (ANA) testing was the gold standard method for ANA detection, and the American College of Rheumatology continues to recommend IF for evaluation of ANA. Many commercial labs have recently adopted newer, automated, non-immunofluorescence methods (NEW ANAs), such as EIA (enzyme immunoassay) or immunobead methods to evaluate for the presence of antinuclear antibodies. These new techniques rely on a limited panel of autoantigens in the assay.
The purpose of this study was to evaluate ANAs and SScAB results performed through commercial labs, using both NEW ANA detection techniques and traditional IF, in a consecutive cohort of scleroderma patients seen in the Georgetown Scleroderma Clinic over a one year period.
Methods: Between June 2008 and June 2009, 241 scleroderma patients were evaluated. Patient charts were reviewed for results of NEW ANA, IF-ANA, isolated nucleolar ANA pattern (NuANA), and the SScAB profile including anticentromere (ACA), anti-topoisomerase (Scl-70), U1 RNP, and RNA polymerase III (Pol III) antibodies.Results: The results of this study are summarized in table 1. NEW ANA results were available in 58 patients with 28 patients (48%) testing negative. Of these 28 patients, 22 had either positive IF-ANA or a SScAB recorded: IF-ANA only (n=7), NuANA (n=6), Pol III (n=7), SSB (n=1), U1 RNP (n=1). In the patients with a positive NEW ANA (n=30) the NEW ANA successfully detected all patients with ACA (n=4), Scl-70 (n=13), UI RNP (n=6), and SSA (n=1) antibodies. A positive NEW ANA additionally identified Pol III (n=1), NuANA with a + SSA (n=3), and nonspecific ANA (n=2). However, the NEW ANA failed to identify the NuANA, Pol III antibodies, and other IF-ANA patterns in a significant number of patients (20/22 vs. 6/30, p
The remaining 183 SSc patients did not have NEW ANA testing available. Of these patients, 156 (85%) had positive SScABs or an IF-ANA. ACA was present in 22.4%, Scl-70 in 25%, and U1 RNP in 9.6%. This accounts for 57% of patients who we predict would be identified with the NEW ANA assay. However, patients with other antibodies including Pol III (10.2%), NuANA (19.2%), and nonspecific ANA patterns (13.5%), account for 40% of the scleroderma patients in our population, and we predict these patients would not be identified using NEW ANA assays.
Conclusions: Immunofluorescence ANA should be performed in all patients in whom there is clinical suspicion for scleroderma. Physicians should remain skeptical of negative ANAs in patients with clinical evidence of scleroderma.
Karen Mallet | EurekAlert!
WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf
First form of therapy for childhood dementia CLN2 developed
25.04.2018 | Universitätsklinikum Hamburg-Eppendorf
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences